Ghost Tree Capital’s Ascendis Pharma A/S ASND Stock Holding History

Ghost Tree Capital’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$7.84M	Sell	52,500 -34,221	-39%	-$4.62M	2.37%	15
2024 Q2	$11.8M	Buy	+86,721	New	+$11.8M	3.7%	7
2024 Q1	–	Sell	-20,000	Closed	-$2.52M	–	76
2023 Q4	$2.52M	Sell	20,000 -65,000	-76%	-$6.48M	0.82%	36
2023 Q3	$7.96M	Sell	85,000 -15,000	-15%	-$1.4M	2.62%	9
2023 Q2	$8.93M	Sell	100,000 -10,000	-9%	-$870K	2.95%	12
2023 Q1	$11.8M	Sell	110,000 -20,000	-15%	-$2.29M	3.49%	7
2022 Q4	$15.9M	Buy	130,000 +35,000	+37%	+$4.06M	6.78%	3
2022 Q3	$9.81M	Buy	95,000 +20,000	+27%	+$1.9M	2.75%	15
2022 Q2	$6.97M	Sell	75,000 -65,000	-46%	-$6.13M	3.63%	11
2022 Q1	$16.4M	Sell	140,000 -50,000	-26%	-$5.79M	3.57%	3
2021 Q4	$25.6M	Buy	190,000 +70,000	+58%	+$10.4M	9.16%	1
2021 Q3	$19.1M	Sell	120,000 -15,000	-11%	-$2.05M	5.59%	2
2021 Q2	$17.8M	Hold	135,000	–	–	4.88%	3
2021 Q1	$17.4M	Buy	135,000 +30,000	+29%	+$4.56M	4.09%	5
2020 Q4	$17.5M	Sell	105,000 -25,000	-19%	-$4.13M	3.9%	8
2020 Q3	$20.1M	Buy	130,000 +65,000	+100%	+$9.34M	5.8%	3
2020 Q2	$9.61M	Sell	65,000 -85,000	-57%	-$11.7M	2.54%	17
2020 Q1	$16.9M	Sell	150,000 -50,000	-25%	-$6.5M	4.48%	6
2019 Q4	$27.8M	Buy	200,000 +50,000	+33%	+$5.55M	5.3%	3
2019 Q3	$14.4M	Sell	150,000 -75,000	-33%	-$8.37M	3.68%	10
2019 Q2	$25.9M	Sell	225,000 -160,000	-42%	-$19.1M	5.37%	6
2019 Q1	$45.3M	Buy	385,000 +260,000	+208%	+$22.8M	11.84%	1
2018 Q4	$7.83M	Sell	125,000 -100,000	-44%	-$6.28M	2.84%	13
2018 Q3	$15.9M	Buy	225,000 +50,000	+29%	+$3.44M	3.39%	9
2018 Q2	$11.6M	Buy	175,000 +35,000	+25%	+$2.3M	3.43%	8
2018 Q1	$9.16M	Sell	140,000 -110,000	-44%	-$6.18M	1.85%	15
2017 Q4	$10M	Buy	250,000 +50,000	+25%	+$1.82M	2.35%	14
2017 Q3	$7.25M	Buy	+200,000	New	+$5.74M	1.54%	25
2016 Q3	–	Sell	-100,000	Closed	-$1.33M	–	89
2016 Q2	$1.33M	Buy	+100,000	New	+$1.54M	0.38%	51
2015 Q4	–	Sell	-97,135	Closed	-$1.72M	–	50
2015 Q3	$1.72M	Buy	97,135 +33,396	+52%	+$650K	0.77%	50
2015 Q2	$1.13M	Buy	+63,739	New	+$1.12M	0.37%	56

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Ghost Tree Capital's ASND Position: Q3 2024 in Review

Ghost Tree Capital reduced its Ascendis Pharma A/S (ASND) stake by 39% in Q3 2024, selling an estimated $4.62M and leaving 52,500 shares worth $7.84M. The position accounts for 2.37% of the portfolio, ranked #15.

Ghost Tree Capital first reported a position in ASND in Q2 2015 and has held it in 31 quarters since. The position peaked at $45.3M in Q1 2019. 219 funds tracked by Wall St. Rank hold ASND as of Q3 2024.

Ghost Tree Capital held 52,500 shares of Ascendis Pharma A/S worth $7.84M as of Q3 2024.
Ghost Tree Capital sold 34,221 Ascendis Pharma A/S shares in Q3 2024, an estimated $4.62M.
Ascendis Pharma A/S made up 2.37% of Ghost Tree Capital's portfolio in Q3 2024, its #15 holding.
Ghost Tree Capital first reported a position in Ascendis Pharma A/S in Q2 2015 and has held it in 31 quarters since.
Ghost Tree Capital's Ascendis Pharma A/S position peaked at $45.3M in Q1 2019.
219 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.